Please login to the form below

Not currently logged in
Email:
Password:

Gilead settles patent dispute with Teva over Viread generic

Launch of generic HIV drug held back until December 2017

Gilead Sciences

Gilead Sciences has settled a patent dispute with Teva over its HIV and hepatitis drug Viread ahead of a US court case to test the strength of its intellectual property.

No financial terms of the settlement have been disclosed, but according to a Gilead statement, Teva has agreed to hold off on launching a generic version of Viread (tenofovir disoproxil fumarate) until December 15, 2017, when the US patent on the drug expires.

The litigation between the two companies on the validity of Gilead's Viread patent had been due to come to trial later today in the District Court for the Southern District of New York.

Tenofovir disoproxil fumarate has been a massive success for Gilead since it first launched in 2001, both in the Viread brand and as a component of the company's combination treatments for HIV and hepatitis B.

Viread achieved sales of $850m last year. Meanwhile Gilead's entire antiviral franchise of five products - all of which contain the active ingredient - brought in $8.14bn out of total product sales of $9.40bn.

The deal also buys time for Gilead to bring its Viread follow-up tenofovir alafenamide fumarate (TAF) to market. TAF entered the phase III testing stage last year and has been designed to reduce some of the side effects of its parent compound including the risk of renal impairment and bone thinning.

"This settlement removes some uncertainty and minimises further distraction and investment of human and financial resources associated with this litigation," said Gilead's chief operating officer John Milligan in a statement.

Previously, Gilead has successfully defended its Viread patent estate in US court cases which took place in 2008 and 2010.

20th February 2013

From: Sales, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics